Jaleh Fallah1, Adam J Olszewski2,3. 1. a Cleveland Clinic Taussig Cancer Institute , Cleveland , OH , USA. 2. b The Warren Alpert Medical School of Brown University , Providence , RI , USA. 3. c Division of Hematology-Oncology , Rhode Island Hospital , Providence , RI , USA.
Abstract
OBJECTIVES: To examine the use of splenectomy, chemotherapy, and subsequent overall survival (OS) in contemporary patients with splenic lymphomas. METHODS: We analyzed records of 6450 patients with various splenic lymphomas recorded in the National Cancer Data Base (2004-2013). Survival was compared using Mantel-Byer test to account for guarantee-time bias, stratified by age, sex, comorbidities, and lymphoma stage. RESULTS: Splenectomy rate was overall 58%, and varied from 49% in splenic marginal zone (SMZL) to 77% in follicular lymphoma (FL). It significantly decreased across all histologies over time (overall from 69% in 2004, to 44% in 2013). Thirty-day mortality after splenectomy was 4%. Chemotherapy use varied from 40% in FL to 76% in diffuse large B-cell lymphoma (DLBCL), but increased significantly only for SMZL and T-cell lymphomas over time. Overall, 57% of splenectomies were performed as diagnostic procedures, which was significantly less common in academic hospitals (p < 0.0001). Following a diagnostic splenectomy, chemotherapy was not administered to 29% of patients with DLBCL, 49% with mantle cell, and 42% with T-cell lymphomas. Median OS ranged from 12.4 years for FL to 1.0 year for T-cell lymphomas. We found no association between performance of splenectomy and OS across all histologies. Patients with DLBCL who did not receive chemotherapy after a diagnostic splenectomy had significantly worse OS (p = 0.001). The association between post-splenectomy chemotherapy and OS was not observed in FL or SMZL. CONCLUSION: many splenic lymphomas may be treated without surgery, but a high proportion of diagnostic splenectomies indicates an ongoing need for less invasive diagnostic modalities.
OBJECTIVES: To examine the use of splenectomy, chemotherapy, and subsequent overall survival (OS) in contemporary patients with splenic lymphomas. METHODS: We analyzed records of 6450 patients with various splenic lymphomas recorded in the National Cancer Data Base (2004-2013). Survival was compared using Mantel-Byer test to account for guarantee-time bias, stratified by age, sex, comorbidities, and lymphoma stage. RESULTS: Splenectomy rate was overall 58%, and varied from 49% in splenic marginal zone (SMZL) to 77% in follicular lymphoma (FL). It significantly decreased across all histologies over time (overall from 69% in 2004, to 44% in 2013). Thirty-day mortality after splenectomy was 4%. Chemotherapy use varied from 40% in FL to 76% in diffuse large B-cell lymphoma (DLBCL), but increased significantly only for SMZL and T-cell lymphomas over time. Overall, 57% of splenectomies were performed as diagnostic procedures, which was significantly less common in academic hospitals (p < 0.0001). Following a diagnostic splenectomy, chemotherapy was not administered to 29% of patients with DLBCL, 49% with mantle cell, and 42% with T-cell lymphomas. Median OS ranged from 12.4 years for FL to 1.0 year for T-cell lymphomas. We found no association between performance of splenectomy and OS across all histologies. Patients with DLBCL who did not receive chemotherapy after a diagnostic splenectomy had significantly worse OS (p = 0.001). The association between post-splenectomy chemotherapy and OS was not observed in FL or SMZL. CONCLUSION: many splenic lymphomas may be treated without surgery, but a high proportion of diagnostic splenectomies indicates an ongoing need for less invasive diagnostic modalities.
Entities:
Keywords:
Epidemiology; diffuse large B-cell lymphoma; follicular lymphoma; mantle cell lymphoma; splenectomy; splenic marginal zone lymphoma
Authors: Melissa Lumish; Lorenzo Falchi; Brandon S Imber; Michael Scordo; Gottfried von Keudell; Erel Joffe Journal: J Hematol Oncol Date: 2021-01-06 Impact factor: 17.388
Authors: Rami Abdulbaki; Parastou Tizro; Victor E Nava; Maria Gomes da Silva; João L Ascensão Journal: Curr Oncol Date: 2021-11-18 Impact factor: 3.677
Authors: Robert Naples; Alexander Bertke; Aldo Fafaj; Samuel J Zolin; Jonah D Thomas; Clayton Petro; David Krpata; Ajita S Prabhu; Michael J Rosen; Steven Rosenblatt Journal: World J Surg Date: 2020-09 Impact factor: 3.352